Trial
NCT03699202
Anti-RSV Study in Chinese Patients (ASCENT)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Collaborators
—
Condition
Respiratory Syncytial Virus Infections
Intervention
AK0529
Why stopped
The study was terminated early due to COVID-19-related enrollment disruptions, not as a result of any product safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-22